TD Cowen lowered the firm’s price target on Amwell (AMWL) to $10 from $12 and keeps a Hold rating on the shares. The firm updated its model following Q2 results but said while the DHA extension is a positive, its reduced scope which excludes Behavioral health and automated care, is an unfortunate development.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell Reports Q2 2025 Financial Results and Strategic Progress
- American Well’s Hold Rating: Balancing Revenue Growth Challenges and Opportunities Amid DHA Contract Changes
- Amwell sees Q3 revenue $53M-$56M, consensus $63.2M
- Amwell cuts FY25 revenue view to $245M-$250M from $250M-$260M
- Amwell reports Q2 EPS ($1..24), consensus ($1.11)